You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Additionally, Cancer Genetics noted that last week it sold off its clinical laboratory business to siParadigm, a specialty reference laboratory, for about $1 million.
Interpace Diagnostics' ThyGeNext and ThyraMir thyroid cancer assays are now covered for about 2.5 million patients in Philadelphia and Southeastern Pennsylvania.
The firm said its growth was driven in part by increasing sales volumes of its gastrointestinal PancraGen business and endocrine ThyGeNext/ThyraMir business.
With the approval of its ThyraMIR diagnostic assay, the firm said that physicians will have access to its thyroid product suite across several specimen types.
For full-year 2018 the firm's revenues rose 38 percent to $21.9 million from $15.9 million a year ago.
The firm will use the proceeds for working capital, capital payments, business development, research and development payments, and technology and business acquisitions.
The company beat the consensus Wall Street estimate on the top line and guided to 2018 revenues of between $21 million and $22 million.
A brief recap of Genetics/Genomics news the week of Oct 5, 2018: OncoDNA, Interpace Diagnostics, B. Braun Melsungen & CeGat, and Premaitha
The firm will begin selling its ThyGeNext thyroid cancer diagnostic tool to physicians in New York and Pennsylvania in combination with ThyraMir.
Priorities for Q3 include the continued buildup of a commercial launch for the company's BarreGEN test. The firm has started a second clinical validation study for the test.
A UK study on mixing SARS-CoV-2 vaccines is expanding to include vaccines developed by additional companies, according to the Guardian.
According to Science, the US National Academy of Sciences is poised to eject two members accused of sexual harassment.
In Nucleic Acids Research this week: machine learning approach to detect DNA-bound proteins, CRISPR-based method for activating specific gene targets, and more.
The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.